Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.

The president-elect might bring back efforts to make other countries pay more for drugs, but there are pitfalls.

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

To the Filipino doctor's utter dissapointment, he did not receive any financial compensation for his milestone discovery.